1 Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023–38. doi:10.1016/S0140-6736(16)30173-8
2 Wegner N, Lundberg K, Feldmann M, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of RA. Immunol Rev 2010;233:34–54.
3 Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti- cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review. Ann Rheum Dis 2006;65:845–51. doi:10.1136/ard.2006.051391
4 Whiting PF, Smidt N, Jonathan ACS, et al. Systematic Review: Accuracy of Anti-Citrullinated Peptode Antibodies for Diagnosing Rheumatoid Arthritis. Ann Intern Med 2010;152:456–64.
5 Kroot JAEJ, De Jong BAW, Van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5. doi:10.1002/1529- 0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6
6 Nimmerjahn F, Ravetch J V. Antibody-mediated modulation of immune responses. Immunol Rev 2010;236:265–75. doi:10.1111/j.1600- 065X.2010.00910.x
7 Yamaguchi Y, Nishimura M, Nagano M, et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta - Gen Subj 2006;1760:693–700. doi:10.1016/j.bbagen.2005.10.002
8 Dekkers G, Treffers L, Plomp R, et al. Decoding the human immunoglobulin G- glycan repertoire reveals a spectrum of Fc-receptor- and complement- mediated-effector activities. Front Immunol 2017;8:877. doi:10.3389/fimmu.2017.00877
9 Rademacher TW, Williams P, Dwek R a. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci U S A 1994;91:6123–7. doi:10.1073/pnas.91.13.6123
10 Hess C, Winkler A, Lorenz AK, et al. T cell–independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clin Invest 2013;123:3788–3796. doi:10.1172/JCI65938.3788
11 Ito K, Furukawa J -i., Yamada K, et al. Lack of Galactosylation Enhances the Pathogenic Activity of IgG1 but Not IgG2a Anti-Erythrocyte Autoantibodies. J Immunol 2014;192:581–8. doi:10.4049/jimmunol.1302488
12 Böhm S, Schwab I, Lux A, et al. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012;34:443–53. doi:10.1007/s00281-012-0308-x
13 Ohmi Y, Ise W, Harazono A, et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat Commun 2016;7:1–12. doi:10.1038/ncomms11205
14 Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL- 23-T H 17 axis determines the onset of autoimmune disease. Nat Immunol 2017;18:104–13. doi:10.1038/ni.3579
15 Pagan JD, Kitaoka M, Anthony RM. Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease. Cell 2018;172:564- 577.e13. doi:10.1016/j.cell.2017.11.041
16 Ma J, Zhu C, Ma B, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012;2012. doi:10.1155/2012/827480
17 Chevalier N, Macia L, Tan JK, et al. The Role of Follicular Helper T Cell Molecules and Environmental Influences in Autoantibody Production and Progression to Inflammatory Arthritis in Mice. Arthritis Rheumatol 2016;68:1026–38. doi:10.1002/art.39481
18 Moschovakis GL, Bubke A, Friedrichsen M, et al. T cell specific Cxcr5 deficiency prevents rheumatoid arthritis. Sci Rep 2017;7:1–13. doi:10.1038/s41598-017-08935-6
19 Akiyama M, Yasuoka H, Yamaoka K, et al. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res Ther 2016;18:167. doi:10.1186/s13075-016-1064-4
20 Frey O, Bruns L, Morawietz L, et al. B cell depletion reduces the number of autoreactive T helper cells and prevents glucose-6-phosphate isomerase- induced arthritis. PLoS One 2011;6:4–11. doi:10.1371/journal.pone.0024718
21 Tanaka-Watanabe Y, Matsumoto I, Iwanami K, et al. B cells play a crucial role as antigen-presenting cells and collaborate with inflammatory cytokines in glucose-6-phosphate isomerase-induced arthritis. Clin Exp Immunol 2009;155:285–94. doi:10.1111/j.1365-2249.2008.03816.x
22 Matsumoto I, Staub A. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science (80- ) 1999;286:1732–5. doi:10.1126/science.286.5445.1732
23 Kouskoff V, Korganow A-S, Duchatelle V, et al. Organ-specific autoimmune disease provoked by systemic autoimmunity. Cell 1996;87:811–22.
24 Korganow AS, Hong J, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451–61. doi:10.1016/S1074-7613(00)80045-X
25 Iwanami K, Matsumoto I, Tanaka-Watanabe Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose- 6-phosphate isomerase. Arthritis Rheum 2008;58:754–63. doi:10.1002/art.23222
26 Buttgereit F, Zhou H, Kalak R, et al. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum 2009;60:1998–2007. doi:10.1002/art.24619
27 Arnett FC, Edworthy, Steven M, Bloch DA, et al. Revised Criteria For The Classification Of Rheumatoid Arthritis. Arthritis Rheum 1988;31:315–24.
28 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81. doi:10.1002/art.27584
29 Togayachi A, Tomioka A, Fujita M, et al. Identification of Poly-N- Acetyllactosamine-Carrying Glycoproteins from HL-60 Human Promyelocytic Leukemia Cells Using a Site-Specific Glycome Analysis Method, Glyco- RIDGE. J Am Soc Mass Spectrom 2018;29:1138–52. doi:10.1007/s13361- 018-1938-6
30 Oefner CM, Winkler A, Hess C, et al. Tolerance induction with T cell- dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol 2012;129:1647–55. doi:10.1016/j.jaci.2012.02.037
31 Yoshioka T, Nakajima A, Akiba H, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000;30:2815–23.
32 Horai R, Nakajima A, Habiro K, et al. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004;114:1603–11. doi:10.1172/JCI20742
33 Gwyer Findlay E, Danks L, Madden J, et al. OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci 2014;111:2289–94. doi:10.1073/pnas.1321071111
34 Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, et al. Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Res Ther 2014;16:1–9. doi:10.1186/s13075-014-0474-4
35 Engdahl C, Bondt A, Harre U, et al. Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: A potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women. Arthritis Res Ther 2018;20:1–11. doi:10.1186/s13075-018-1586-z
36 Park HJ, Park HS, Lee JU, et al. Sex-based selectivity of PPARγ regulation in Th1, Th2, and Th17 differentiation. Int J Mol Sci 2016;17:1–11. doi:10.3390/ijms17081347
37 Monteiro C, Kasahara T, Castro J, et al. Pregnancy favors the expansion of circulating functional follicular helper T cells. J Reprod Immunol 2017;121:1– 10.
38 Bartsch YC, Rahmöller J, Mertes MMM, et al. Sialylated autoantigen-reactive IgG antibodies attenuate disease development in autoimmune mouse models of Lupus nephritis and rheumatoid arthritis. Front Immunol 2018;9. doi:10.3389/fimmu.2018.01183
39 Tamam B, Kathrin W, Annika K. Glycosylation of autoantibodies: Insights into the mechanisms of immune thrombocytopenia. Thromb Haemost 2013;110:1259–66.
40 Jacquemin C, Schmitt N, Contin-Bordes C, et al. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. Immunity 2015;42:1159–70. doi:10.1016/j.immuni.2015.05.012
41 Cui D, Lv Y, Yuan X, et al. Increased expressions of OX40 and OX40 ligand in patients with primary immune thrombocytopenia. J Immunol Res 2019;2019. doi:10.1155/2019/6804806
論文の公開元へ
